Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Parkinson Disease 4”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Large-scale testing (Phase 3)Study completedNCT03950674
What this trial is testing

Study of Pemetrexed+Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-3475-189/KEYNOTE-189)-Japan Extension Study

Who this might be right for
Non-Small-Cell Lung Carcinoma
Merck Sharp & Dohme LLC 40
Not applicableStudy completedNCT04518059
What this trial is testing

Misfolded Proteins in the Skin of People With Parkinson's Disease and Other Parkinsonism

Who this might be right for
Parkinson DiseaseParkinsonismDementia With Lewy Bodies+3 more
University Hospitals Cleveland Medical Center 184
Post-approval studies (Phase 4)Study completedNCT01711866
What this trial is testing

A Phase 4, Open-label Study to Assess the Feasibility and Efficacy on Motor and Non-motor Symptoms of Switching From Pramipexole or Ropinirole to Rotigotine Transdermal Patch in Subjects With Advanced Idiopathic Parkinson's Disease

Who this might be right for
Advanced Idiopathic Parkinson's Disease
UCB BIOSCIENCES GmbH 87
Testing effectiveness (Phase 2)Active Not RecruitingNCT04626479
What this trial is testing

Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)

Who this might be right for
Carcinoma, Renal Cell
Merck Sharp & Dohme LLC 400
Large-scale testing (Phase 3)Study completedNCT02252042
What this trial is testing

Pembrolizumab (MK-3475) Versus Standard Treatment for Recurrent or Metastatic Head and Neck Cancer (MK-3475-040/KEYNOTE-040)

Who this might be right for
Head and Neck Squamous Cell Cancer
Merck Sharp & Dohme LLC 495
Large-scale testing (Phase 3)Study completedNCT04934722
What this trial is testing

Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)-China Extension

Who this might be right for
Metastatic Hormone-Sensitive Prostate Cancer
Merck Sharp & Dohme LLC 186
Not applicableStudy completedNCT06900686
What this trial is testing

Clinical Application of PD-1 Inhibitor in Colorectal Cancer for Improving Survival

Who this might be right for
Rectal CancerColon Cancer
Yanhong Deng 458
Not applicableLooking for participantsNCT04724941
What this trial is testing

Prodromal Alpha-Synuclein Screening in Parkinson's Disease Study

Who this might be right for
Parkinson Disease
University Hospital Schleswig-Holstein 2,000
Early research (Phase 1)UnknownNCT04593511
What this trial is testing

To Evaluate the Safety, Tolerability and Pharmacokinetics of Four Formulations of LY03009 in Healthy Volunteers

Who this might be right for
Parkinson's Disease
Luye Pharma Group Ltd. 40
Testing effectiveness (Phase 2)Study completedNCT05342636
What this trial is testing

Combination Therapies With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer (MK-3475-06A)

Who this might be right for
Esophageal Squamous Cell Carcinoma (ESCC)
Merck Sharp & Dohme LLC 90
Testing effectiveness (Phase 2)Active Not RecruitingNCT04995523
What this trial is testing

AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC

Who this might be right for
Non-Small-Cell Lung Carcinoma
AstraZeneca 212
Early research (Phase 1)Study completedNCT03010176
What this trial is testing

Study of Ulevostinag (MK-1454) Alone or in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors or Lymphomas (MK-1454-001)

Who this might be right for
Solid TumorsLymphoma
Merck Sharp & Dohme LLC 156
Large-scale testing (Phase 3)Study completedNCT05298423
What this trial is testing

Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006)

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Merck Sharp & Dohme LLC 610
Testing effectiveness (Phase 2)Study completedNCT03664024
What this trial is testing

Biomarkers of Response to Pembrolizumab Combined With Chemotherapy in Non-Small Cell Lung Cancer (KEYNOTE-782, MK-3475-782)

Who this might be right for
Non-Small Cell Lung Cancer
Merck Sharp & Dohme LLC 118
Testing effectiveness (Phase 2)Study completedNCT04704219
What this trial is testing

Pembrolizumab Plus Lenvatinib for First-line Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma (1L nccRCC) (MK-3475-B61)

Who this might be right for
Renal Cell Carcinoma
Merck Sharp & Dohme LLC 160
Early research (Phase 1)Study completedNCT06460961
What this trial is testing

MK-6837 as a Monotherapy and Combination Therapy in Participants With Advanced/Metastatic Solid Tumors (MK-6837-001)

Who this might be right for
Neoplasm Metastasis
Merck Sharp & Dohme LLC 40
Large-scale testing (Phase 3)Active Not RecruitingNCT04736706
What this trial is testing

Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)

Who this might be right for
Carcinoma, Renal Cell
Merck Sharp & Dohme LLC 1,854
Testing effectiveness (Phase 2)Active Not RecruitingNCT04626518
What this trial is testing

Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03)

Who this might be right for
Carcinoma, Renal Cell
Merck Sharp & Dohme LLC 370
Large-scale testing (Phase 3)Study completedNCT03358472
What this trial is testing

Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)

Who this might be right for
Head and Neck Cancer
Incyte Corporation 89
Testing effectiveness (Phase 2)UnknownNCT05505877
What this trial is testing

Phase I/IIa Study of BR790 in Combination With Tislelizumab in Adult Subjects With Advanced Solid Tumors

Who this might be right for
Advanced Solid Tumor
Shanghai Gopherwood Biotech Co., Ltd. 160
Next Page